Clin Asst Prof Koo Si-Lin

MBBS (S’pore), MRCP (UK), MMed (In. Med)

Senior Consultant

National Cancer Centre Singapore National Cancer Centre Singapore

Specialty: Medical Oncology

Clinical Appointments

Senior Consultant

NCCS Oncology @ SKH

Academic Appointments

Clinical Asst Professor at Duke-NUS Medical School

About

Dr. Koo Si-Lin is a Senior Consultant Medical Oncologist specialising in gastrointestinal cancers with a focus on colorectal cancer. Her clinical practice centres on providing comprehensive care for patients with gastrointestinal malignancies. In addition to patient care, she is actively involved in clinical research, serving as Principal Investigator in various trials in colorectal cancer. Her research work includes collaborations with various academic institutions, contributing to the field through peer-reviewed publications. At NCCS, she combines clinical care with research to support evidence-based treatment approaches for patients with gastrointestinal cancers.

Education and Training

  • MRCP, Royal College of Physicians 
  • MMed, National University of Singapore 
  • MBBS, National University of Singapore 

Professional Appointments and Committee Memberships

  • Senior Consultant, Medical Oncology 
  • Clinical Asst Professor, Duke-NUS Graduate Medical School 
  • Singapore Society of Oncology

Awards

Research Interests

Research Trials

  • An open label, single-arm, Phase II Neoantigen (NA) Dendritic Cell (DC) vaccine and anti-PD1 (Nivolumab) as adjuvant treatment in resected hepatocellular carcinoma (HCC) (Group A) and liver metastases from colorectal cancer (CRLM) (Group B) (PI)
  • A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Sub-jects with Metastatic Colorectal Cancer (Site-PI) 
  • Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carci-noma (MK-3475-177/KEYNOTE-177) (Site-PI)

Publications

  • Simoni Y, Fehlings M, Kløverpris HN, McGovern N, Koo SL, Loh CY, Lim S, Kurioka A, Fergusson JR, Tang CL, Kam MH, Dennis K, Lim TK, Fui AC, Hoong CW, Chan JK, Curot-to de Lafaille M, Narayanan S, Baig S, Shabeer M, Toh SE, Tan HK, Anicete R, Tan EH, Takano A, Klenerman P, Leslie A, Tan DS, Tan IB, Ginhoux F, Newell EW. Human Innate Lymphoid Cell Subsets Possess Tissue-Type Based Heterogeneity in Phenotype and Fre-quency. Immunity. 2017 Jan 17;46(1):148-161. [IF: 19.7] 
  • Ng SB, Chua C, Ng M, Gan A, Poon PS, Teo M, Fu C, Leow WQ, Lim KH, Chung A, Koo SL, Choo SP, Ho D, Rozen S, Tan P, Wong M, Burkholder WF, Tan IB. Individualised mul-tiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery. Sci Rep. 2017 Jan 19;7:40737. [IF: 4.1] 
  • Simoni Y, Fehlings M, Kløverpris HN, McGovern N, Koo SL, Loh CY, Lim S, Kurioka A, Fergusson JR, Tang CL, Kam MH, Dennis K, Lim TKH, Fui ACY, Hoong CW, Chan JKY, Curotto de Lafaille M, Narayanan S, Baig S, Shabeer M, Toh SES, Tan HKK, Anicete R, Tan EH, Takano A, Klenerman P, Leslie A, Tan DSW, Tan IB, Ginhoux F, Newell EW. Human Innate Lymphoid Cell Subsets Possess Tissue-Type Based Heterogeneity in Phenotype and Frequency. Immunity. 2018 May 15;48(5):1060. doi: 10.1016/j.immuni.2018.04.028. [IF:21.5] 
  • Simoni Y, Becht E, Fehlings M, Loh CY, Koo SL, Teng KWW, Yeong JPS, Nahar R, Zhang T, Kared H, Duan K, Ang N, Poidinger M, Lee YY, Larbi A, Khng AJ, Tan E, Fu C, Mathew R, Teo M, Lim WT, Toh CK, Ong BH, Koh T, Hillmer AM, Takano A, Lim TKH, Tan EH, Zhai W, Tan DSW, Tan IB, Newell EW. Bystander CD8+ T cells are abundant and pheno-typically distinct in human tumour infiltrates. Nature. 2018 May;557(7706):575-579. doi: 10.1038/s41586-018-0130-2. [IF: 43.1] 
  • Ragulan C, Eason K, Fontana E, Nyamundanda G, Tarazona N, Patil Y, Poudel P, Lawlor RT, Del Rio M, Koo SL, Tan WS, Sclafani F, Begum R, Teixeira Mendes LS, Martineau P, Scarpa A, Cervantes A, Tan IB, Cunningham D, Sadanandam A. Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes. Sci Rep. 2019 May 21;9(1):7665. doi: 10.1038/s41598-019-43492-0. [IF: 4.0] 
  • Li S, Simoni Y, Becht E, Loh CY, Li N, Lachance D, Koo SL, Lim TP, Tan EKW, Mathew R, Nguyen A, Golovato J, Berkson JD, Prlic M, Lee B, Minot SS, Nagarajan N, Dey N, Tan DSW, Tan IB, Newell EW. 12. Human Tumor-Infiltrating MAIT Cells Display Hallmarks of Bacterial Antigen Recognition in Colorectal Cancer. Cell Rep Med. 2020 Jun 23;1(3):100039. doi: 10.1016/j.xcrm.2020.100039. [IF : 9.4] 
  • Lam JH, Hong M, Koo SL, Chua CWL, Lim KL, Wee F, Wan WK, Leow WQ, Yeo JG, Tan IBH, Yeong J, Lim TKH, Lim TS. 14. CD30+OX40+ Treg is associated with improved overall survival in colorectal cancer. Cancer Immunol Immunother. 2021 Feb 2. doi: 10.1007/s00262-021-02859-x. Epub ahead of print. [IF: 7.0] 
  • Zhu G, Guo YA, Ho D, Poon P, Poh ZW, Wong PM, Gan A, Chang MM, Kleftogiannis D, Lau YT, Tay B, Lim WJ, Chua C, Tan TJ, Koo SL, Chong DQ, Yap YS, Tan I, Ng S, Skan-derup AJ. Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA bur-den. Nat Commun. 2021 Apr 13;12(1):2229. doi: 10.1038/s41467-021-22463-y.[IF: 14.9] 
  • Tai D, Loke K, Gogna A, Kaya NA, Tan SH, Hennedige T, Ng D, Irani F, Lee J, Lim JQ, Too CW, Ng MCH, Tham CK, Lam J, Koo SL, Chong HS, Goh GB, Huang HL, Venkatanarasim-ha N, Lo R, Chow PKH, Goh BKP, Chung A, Toh HC, Thng CH, Lim TKH, Yeong J, Zhai W, Chan CY, Choo SP. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial. Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1025-1035. doi: 10.1016/S2468-1253(21)00305-8. Epub 2021 Oct 23. [IF: 4.9] 
  • Shamin Li, Summer Zhuang, Antja Heit, Si-Lin Koo, Aaron C. Tan, I-Ting Chow, William W. Kwok, Iain Beehuat Tan, Daniel S.W. Tan, Yannick Simoni, Evan W. Newell. Bystander CD4+ T cells infiltrate human tumors and are phenotypically distinct. OncoImmunology Vol. 11, Issue 1. Jan 2022. 
  • Joanito I, Wirapati P, Zhao N, Nawaz Z, Yeo G, Lee F, Eng CLP, Macalinao DC, Kahraman M, Srinivasan H, Lakshmanan V, Verbandt S, Tsantoulis P, Gunn N, Venkatesh PN, Poh ZW, Nahar R, Oh HLJ, Loo JM, Chia S, Cheow LF, Cheruba E, Wong MT, Kua L, Chua C, Ngu-yen A, Golovan J, Gan A, Lim WJ, Guo YA, Yap CK, Tay B, Hong Y, Chong DQ, Chok AY, Park WY, Han S, Chang MH, Seow-En I, Fu C, Mathew R, Toh EL, Hong LZ, Skanderup AJ, DasGupta R, Ong CJ, Lim KH, Tan EKW, Koo SL, Leow WQ, Tejpar S, Prabhakar S, Tan IB. Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer. Nat Genet. 2022 Jun 30;54(7):963–975 1
  • Chong CX, Koh FH, Tan HL, Sivarajah SS, Ng JL, Ho LM, Aw DK, Koo WH, Han S, Koo SL, Yip CS, Wang FQ, Foo FJ, Tan WJ. The impact of short-course total neoadjuvant thera-py, long-course chemoradiotherapy, and upfront surgery on the technical difficulty of total mesorectal excision: an observational study with an intraoperative perspective. Ann Colo-proctol. 2024 Oct;40(5):451-458. doi: 10.3393/ac.2023.00899.0128. Epub 2024 Sep 19. PMID: 39477330; PMCID: PMC11532385.